Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : PHN-010
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : TCGX
Deal Size : $120.0 million
Deal Type : Series B Financing
Pheon Therapeutics Announces $120M Series B Financing for ADC Pipeline Development
Details : The financing aims to fund the clinical development of company lead product PHN-010, which is being evaluated in the early-stage trial studies for the treatment of neoplasms.
Brand Name : PHN-010
Molecule Type : Large molecule
Upfront Cash : Undisclosed
May 21, 2024
Lead Product(s) : PHN-010
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : TCGX
Deal Size : $120.0 million
Deal Type : Series B Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Recipient : Biocytogen
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Biocytogen Pharmaceuticals Enters into License Agreement with Pheon Therapeutics
Details : Under the terms of the agreement, Pheon will develop and commercialize a next generation antibody-drug conjugate (ADC) for a wide range of hard-to-treat cancers developed using Biocytogen’s proprietary RenMiceTM platforms.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 05, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Recipient : Biocytogen
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : PHN-010
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Brandon Capital
Deal Size : $68.0 million
Deal Type : Series A Financing
Brandon Capital Co-Leads USD 68M Series A Financing of London-Based ADC Company Pheon Therapeutics
Details : The investment will enable Pheon to advance its lead ADC program PHN-010, to clinical proof-of-concept and establish a pipeline of novel ADCs. Pheon’s lead program exploits a novel target that is highly expressed in a broad range of solid tumors.
Brand Name : PHN-010
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 28, 2022
Lead Product(s) : PHN-010
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Brandon Capital
Deal Size : $68.0 million
Deal Type : Series A Financing
LOOKING FOR A SUPPLIER?
Reset All
